Joseph Kim, MD
Biography
Research & Publications
Patient Care
News
Locations
Appointments
Biography
Dr. Joseph Kim received his medical oncology fellowship training at National Cancer Institute, NIH, where he received training in development of clinical trials of novel cancer therapies for genitourinary cancers and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). Dr. Kim specializes in early phase clinical trials of novel cancer therapies and in caring for patients with prostate cancer, urinary tract and bladder cancer, penile cancer, testicular cancer, and other genitourinary malignancies. Dr. Kim research interest include DNA repair pathway, mTOR pathway, tumor hypoxia, cancer immunotherapy. Dr. Kim is currently spearheading several NCI-sponsored clinical trials of PARP inhibitor, olaparib in combination with a VEGFR tyrosine kinase inhibitor, cediranib, in prostate cancer (CTEP# 9984) and in other advanced solid tumors (CTEP #9881) as well as a mTOR inhibitor, sapanisertib (aka TAK228 or MLN0128) for advanced urinary tract cancers (CTEP #9767) as the Study Chair. He is an active member of Society of Immunotherapy of Cancer, AACR and ASCO.
Education & Training
- MDWake Forest University School of Medicine (2007)
- FellowNational Institutes of Health
- ResidentEmory University School of Medicine
- Board CertificationAB of Internal Medicine, Internal Medicine (2010)
Honors & Recognition
Award | Awarding Organization | Date |
---|---|---|
Young Investigator Award | Conquer Cancer Foundation, American Society of Clinical Oncology | 2013 |
Merit Award | Conqer Cancer Foundation, American Society of Clinical Oncology | 2013 |
Departments & Organizations
- Cancer Signaling Networks
- Early Drug Development Program
- Internal Medicine
- Medical Oncology
- Phase I Program
- Prostate & Urologic Cancers Program
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine